Clinical trial
A Randomized, Double-Blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder
NCT04113941 is registered in ClinicalTrials.gov with Medy-Tox as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of MEDITOXIN® in Subject With Idiopathic Overactive Bladder
- Lead sponsor
- Medy-Tox
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- August 23, 2019
- Completion date
- August 31, 2021
- Enrollment
- 216 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
overactive bladder